Escudier, 2009 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of sorafenib versus interferon alpha in patients with untreated, advanced renal cancer.

        Z

J Clin Oncol 2009;27:1280-9  



Studied treatment oral sorafenib 400 mg twice daily
Control treatment subcutaneous IFN--2a 9 million U three times weekly



Patients patients with untreated, advanced renal cancer.
Group sizes97 / 92
treatment line line 1
cross over



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design Parallel groups

phase 2



EndpointX1N1X0N0TE95% CI PFS - 97 - 92 0,88[0,61; 1,27] OS - 97 - 92 no data0,22,01,0

Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-9     [PMID: 19171708]   link to pdf   add to Mendeley  



Registering number (see trial on clinicaltrials.gov)
Code Name